While soluble TACI was suggested as a biomarker in primary central nervous system lymphoma (50), further studies are warranted to assess whether soluble (p)TACI level are also associated with disease progression and could together with pTACI surface level serve as biomarker in breast cancer. The gene discussed is TNFRSF13B; the disease is breast carcinoma.